While reduced-count MBL not often progresses to CLL, significant-depend MBL progresses to CLL requiring therapy in a fee of 1% to two% per annum. Higher-count MBL is distinguished from Rai 0 CLL determined by whether the B-cell count is above or underneath 5 × 109/L. Though individuals with both equally significant-count MBL and CLL Rai phase 0 ar